European Archives - Page 78 of 1629 - European Medical Journal

Zanubrutinib Improved IgG4-Related Disease Outcomes

Zanubrutinib monotherapy produced significant imaging, clinical, and immunological improvements in active IgG4-RD, supporting further evaluation as a steroid sparing treatment approach.

German Politicians Push for Cancer Survivor Protections

Germany considers new laws to protect cancer survivors from discrimination in insurance, loans and other areas of life.

Richard Shotton on behaviour, bias and better pharma marketing

Behavioural science expert and Astroten founder Richard Shotton explores how behavioural science can improve pharmaceutical marketing.

Enfortumab Vedotin-Induced Skin Reactions Linked to Better Survival

Patients who developed enfortumab vedotin-induced cutaneous adverse events experienced significantly longer progression free and overall survival, suggesting these skin reactions may have prognostic value during treatment.

AI Model Predicted Surgical Risk Before Gastric Cancer Surgery

An AI model improved preoperative risk prediction before gastric cancer surgery, outperforming established clinical scores for postoperative complications and overall survival.

GLP-1 Dual Agonist DD01 Reduced Liver Fat in MASH

An investigational GLP-1 dual agonist, DD01, reduced liver fat in adults with MASLD or MASH in a phase 2 trial.

Single HIV Pill Could Simplify Treatment for Drug-Resistant Patients

A Phase III trial shows a once-daily bictegravir and lenacapavir pill could replace complex HIV treatment regimens for people with drug-resistant virus.

Growth-Adjusted MPA/AA Ratio Provides Reference Values for Children

Growth-adjusted MPA/AA ratio reference values could help place paediatric chest CT findings into developmental context, according to a multicentre retrospective study.

Left Bundle Branch Area Pacing Shows Comparable Tricuspid Outcomes

A matched cohort study found no significant differences in tricuspid regurgitation progression between left bundle branch area pacing and conventional cardiac resynchronisation therapy.

Hospital-at-Home Supported Safe Kidney Transplant Recovery

Early Hospital-at-Home transfer after kidney transplant reduced hospital stay and healthcare costs while maintaining comparable one-year clinical outcomes, graft survival and readmission rates in a propensity score matched study.